arrow_back Back Filing freshness 10-Q Q1 FY2025 SEC EDGAR

LISATA THERAPEUTICS, INC.

LSTA
$1.05 ▼ -0.02 (-1.87%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
66 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
23
Health
Poor
Bearish
auto_awesome

Analytical Summary

LISATA THERAPEUTICS, INC. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $9.5M
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC -48.8%
FCF / Share $-0.34
Trailing P/E
Price / Book 0.9x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

66-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
↓ -100.0%
Net Income Profit after all expenses
$-4.49M
↑ +5.0%
Operating Margin Operating profit as % of sales
-494.9%
↓ -311.4%
FCF / Share Free cash flow per share
$-0.34
↑ +45.8%
Long-Term Debt Long-term obligations
$0.00
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
7
Cash Quality
63

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 17 years · 66 quarters